MEK1 Inhibitor | MAP2K1, inhibitor

MEK1 Inhibitor (PD98059, 2'-amino-3'-methoxyflavone)

Cat. Num. AAA655442

• Gene Names: MAP2K1; CFC3; MEK1; MKK1; MAPKK1; PRKMK1
• Purity: Highly Purified; ~99%
• Synonyms: MEK1 Inhibitor; MEK1 Inhibitor (PD98059; 2'-amino-3'-methoxyflavone); MAP2K1; inhibitor

• Purity/Purification: Highly Purified; ~99%
• Form/Format: Supplied as a pale yellow powder.

• CAS Number: 167869-21-8
• Molecular Formula: C16H13NO3
• Solubility: Soluble in DMSO.
• Preparation and Storage: Lyophilized powder may be stored at -20 degree C. Stable for 12 months at -20 degree C. Reconstitute with DMSO. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap. Further dilutions can be made in assay buffer.

Structure

(Structure of PD 98059)

Related Product Information for MAP2K1, inhibitor

Potent, selective and cell-permeable inhibitor of MAP kinase kinase (also known as MAPK/ERK kinase or MEK kinase). Inhibits phosphorylation of MAP kinase by MAP kinase kinase. PD 98059 does not inhibit MAP kinase itself. IC50 values for PD 98059-induced effects are in the 1-20uM range for many assays; it is somewhat weaker in inhibiting cell growth in monolayers or agar for some cell lines.

Product Categories/Family for MAP2K1, inhibitor

Molecular Biology; MB-Protein Kinase Inhibitors

NCBI and Uniprot Product Information

• NCBI GI #: 187953569
• NCBI GeneID: 5604
• UniProt Accession #: Q02750
• Molecular Weight: 267.28
• NCBI Official Full Name: Mitogen-activated protein kinase kinase 1
• NCBI Official Synonym Full Names: mitogen-activated protein kinase kinase 1
• NCBI Official Symbol: MAP2K1
• NCBI Official Synonym Symbols: CFC3; MEK1; MKK1; MAPKK1; PRKMK1
• NCBI Protein Information: dual specificity mitogen-activated protein kinase kinase 1; MEK 1; MAPKK 1; MAPK/ERK kinase 1; ERK activator kinase 1; protein kinase, mitogen-activated, kinase 1 (MAP kinase kinase 1)
• UniProt Protein Name: Dual specificity mitogen-activated protein kinase kinase 1
• UniProt Gene Name: MAP2K1
• UniProt Synonym Gene Names: MEK1; PRKMK1; MAP kinase kinase 1; MAPKK 1; MKK1; MEK 1
• UniProt Entry Name: MP2K1_HUMAN

NCBI Description

The protein encoded by this gene is a member of the dual specificity protein kinase family, which acts as a mitogen-activated protein (MAP) kinase kinase. MAP kinases, also known as extracellular signal-regulated kinases (ERKs), act as an integration point for multiple biochemical signals. This protein kinase lies upstream of MAP kinases and stimulates the enzymatic activity of MAP kinases upon wide variety of extra- and intracellular signals. As an essential component of MAP kinase signal transduction pathway, this kinase is involved in many cellular processes such as proliferation, differentiation, transcription regulation and development. [provided by RefSeq, Jul 2008]

Uniprot Description

Function: Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of a threonine and a tyrosine residue in a Thr-Glu-Tyr sequence located in the extracellular signal-regulated kinases MAPK3/ERK1 and MAPK1/ERK2, leading to their activation and further transduction of the signal within the MAPK/ERK cascade. Depending on the cellular context, this pathway mediates diverse biological functions such as cell growth, adhesion, survival and differentiation, predominantly through the regulation of transcription, metabolism and cytoskeletal rearrangements. One target of the MAPK/ERK cascade is peroxisome proliferator-activated receptor gamma (PPARG), a nuclear receptor that promotes differentiation and apoptosis. MAP2K1/MEK1 has been shown to export PPARG from the nucleus. The MAPK/ERK cascade is also involved in the regulation of endosomal dynamics, including lysosome processing and endosome cycling through the perinuclear recycling compartment (PNRC), as well as in the fragmentation of the Golgi apparatus during mitosis. Ref.6 Ref.9

Catalytic activity: ATP + a protein = ADP + a phosphoprotein.

Enzyme regulation: Ras proteins such as HRAS mediate the activation of RAF proteins such as RAF1 or BRAF which in turn activate extracellular signal-regulated kinases (ERK) through MAPK (mitogen-activated protein kinases) and ERK kinases MAP2K1/MEK1 and MAP2K2/MEK2. Activation occurs through phosphorylation of Ser-218 and Ser-222. MAP2K1/MEK1 is also the target of negative feed-back regulation by its substrate kinases, such as MAPK1/ERK2. These phosphorylate MAP2K1/MEK1 on Thr-292, thereby facilitating dephosphorylation of the activating residues Ser-218 and Ser-222. Inhibited by serine/threonine phosphatase 2A

By similarity. Many inhibitors have been identified including pyrrole derivatives, TAK-733 (one of a series of 8-methylpyrido[2,3-d]pyrimidine-4,7(3H,8H)-dione derivatives), CH4987655 and RDEA119/BAY 869766.

Subunit structure: Found in a complex with at least BRAF, HRAS1, MAP2K1, MAPK3/ERK1 and RGS14

By similarity. Forms a heterodimer with MAP2K2/MEK2

By similarity. Forms heterodimers with KSR2 which further dimerize to form tetramers

By similarity. Interacts with ARBB2, LAMTOR3, MAPK1/ERK2, MORG1 and RAF1

By similarity. Interacts with PPARG and with isoform 1 of VRK2. Interacts with Yersinia yopJ. Interacts with SGK1. Interacts with BIRC6/bruce. Ref.8 Ref.9 Ref.10 Ref.12 Ref.14

Subcellular location: Cytoplasm › cytoskeleton › microtubule organizing center › centrosome. Cytoplasm › cytoskeleton › microtubule organizing center › spindle pole body. Cytoplasm. Nucleus. Note: Localizes at centrosomes during prometaphase, midzone during anaphase and midbody during telophase/cytokinesis. Ref.6 Ref.9

Tissue specificity: Widely expressed, with extremely low levels in brain. Ref.1

Domain: The proline-rich region localized between residues 270 and 307 is important for binding to RAF1 and activation of MAP2K1/MEK1

By similarity.

Post-translational modification: Phosphorylation at Ser-218 and Ser-222 by MAP kinase kinase kinases (RAF or MEKK1) positively regulates kinase activity. Also phosphorylated at Thr-292 by MAPK1/ERK2 and at Ser-298 by PAK. MAPK1/ERK2 phosphorylation of Thr-292 occurs in response to cellular adhesion and leads to inhibition of Ser-298 phosphorylation by PAK. Ref.3 Ref.7Acetylation by Yersinia yopJ prevents phosphorylation and activation, thus blocking the MAPK signaling pathway.

Involvement in disease: Cardiofaciocutaneous syndrome 3 (CFC3) [MIM:615279]: A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and mental retardation. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. Distinctive features of CFC3 include macrostomia and horizontal shape of palpebral fissures.Note: The disease is caused by mutations affecting the gene represented in this entry. Ref.29 Ref.30

Sequence similarities: Belongs to the protein kinase superfamily. STE Ser/Thr protein kinase family. MAP kinase kinase subfamily.Contains 1 protein kinase domain.